Real life efficacy and safety of secukinumab in elderly psoriasis patients over a 2-year period

Psoriasis prevalence is increasing among elderly subjects. Elderly psoriasis patients represent a challenge for dermatologists due to multiple comorbidities, polypharmacy, immune senescence which lead to increased possibility of adverse events, drug interactions and susceptibility to cancers and infections. Therefore, conventional systemic therapies are often contraindicated with biologics appearing as mainstay for moderate-to-severe disease. However, data on efficacy and safety of biologics in elderly are scant.